Genome-Wide Expression Analysis of a Spinal Muscular Atrophy Model: Towards Discovery of New Drug Targets

Sheena Lee1,*, Arzu Sayin1, Stuart Grice1, Howard Burdett1, Dilair Baban1, Marcel van den Heuvel1

INTRODUCTION

Whole genome expression analysis of animals and tissues offers a novel way of penetrating functional changes in diseased versus normal tissues. Such analysis will map direct and indirect effects of the disease state on gene expression and could identify novel gene targets for drug interference.

Genome wide expression arrays have been made possible by the annotation and gene predictions of whole genome sequence data for human and a large number of model organisms. The genome sequencing work and subsequent species comparisons have also indicated that the genetic differences between species are smaller than anticipated. Both the total number of genes identified and, interestingly, the variety of encoded proteins (and domains) are smaller than expected. Combining these findings with functional genetic analysis has led to the conclusion that for most tissues a group of highly conserved genes is required for differentiation and subsequent function. These genes are expressed and functional in the investigated tissues across the evolutionary tree of animal species. Tissue specific analysis can thus be performed in analogous tissues using a wide variety of model organisms, concentrating on these highly conserved genes.

We have decided to probe the function of known human disease genes by creating and studying mutants in homologues of such genes, in simple model organisms. Here we present a study of gene expression in a simple model organism to identify novel gene pathways that are differentially regulated in normal versus mutant, i.e. diseased, states. The identification of such pathways could potentially lead to the identification of novel drug targets.

SMA is a common recessive genetic disease affecting 1:8000-10,000 across the human population and is characterized by a specific loss of lower motor neurones and muscle atrophy. The genetic cause was identified as the Survival Motor Neurone gene (SMN), however, in the disease situation, SMN protein activity is never completely lost, instead is reduced [1]. The human genome contains two copies of the SMN gene, the activity of the first copy (SMN1) is genetically affected in patients and they therefore rely totally on the activity contributed by the second copy (SMN2). However SMN2 produces less functional protein to varying degrees. The level of remaining SMN activity has been directly correlated to the severity of the phenotypes [2]. In the patient cohort this has lead to distinct groupings, type I being strong, affecting newborns and babies, type II, affecting childhood and type III, affecting late childhood and adults; each group defined on the basis of concrete motor abilities. The generation of an amenable model reflecting human conditions has been complex. The mouse has a single SMN gene and loss of the gene has been shown to lead to early embryonic lethality [3]. Molecular and functional data relating SMN function to SMA have been slow to accumulate and despite the knowledge of the genetic basis of the disease, little is known about the neuromuscular background of the phenotypes.

The SMN gene is expressed ubiquitously in all animals investigated [4]. Extensive biochemical analysis concluded that it is involved in the assembly of large RNA-protein complexes, one of which is the spliceosome (reviewed in [5,6]). Although this work was critical in understanding the function of the SMN protein, it doesn’t explain the neuronal and/or muscle specificity of SMA. Thus it remains unclear why this protein seemingly required for basal functions in the cell, leads to such specific phenotypes when activity falls below a certain threshold. It is possible that a certain

Academic Editor: Ulrich Mueller, University of Giessen, Germany

Received November 1, 2007; Accepted December 3, 2007; Published January 2, 2008

Copyright: © 2008 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: We gratefully acknowledge funding by the Motor Neurone Disease Association, Jennifer Trust and Medical Research Council for the Drosophila SMA model and array validation. We thank the Wellcome Trust Integrative Physiology Initiative on Ion Channels (OXION) for funding the microarray work.

Competing Interests: The authors have declared that no competing interests exist.

* To whom correspondence should be addressed. E-mail: sheena.lee@dpag.ox.ac.uk

† These authors contributed equally to this manuscript.
basal function reaches a critical level in the neuromuscular tissues, or SMN might perform a highly specific function in these tissues.

We have generated a fly model for SMA by knocking out the endogenous smn gene. Unlike in mice, the knock-out animals are born; the embryos survive on the basis of maternal contribution of transcripts coding for normal Smn protein. Maternal contribution, in the homozygous mutant background, runs out during larval stages and leads primarily to neuromuscular phenotypes before the animals die. Because the only genetic aberration in these animals is the reduction of SMN activity, the observed phenotypes must be due to SMN activity reaching a threshold for neuromuscular functionality. Further characterisation showed that these larvae develop clear external motor problems and cell and physiological defects at the motor neuron-muscle junction [7].

To further the molecular understanding of SMA we used our fly model in a genome wide gene expression analysis. We performed micro array analysis of whole animals and SMA affected tissues across normal and smn mutant animals. We used Drosophila whole genome arrays and have produced statistically relevant results. We have validated these using standard methods. In addition we find that, using genetic testing in the fly to investigate functional interactions, novel loci influencing the smn mutant phenotypes can be identified using these data, thus opening the path for novel drug target studies.

RESULTS
Experimental background
We set out to analyse gene expression in whole animals as well as in individual tissues. The latter potentially poses a problem due to the low quantities of starting material that can be obtained from Drosophila. In order to assess gene expression using micro arrays based on the high density GeneChip system, we needed to establish if it was possible to obtain reliable expression data using small quantities of Drosophila RNA.

We compared the same RNA sample at different dilutions, using the “low starting material” amplification procedures to obtain labelled cRNA for the low concentrations [see Material and methods]. The overall yield of labelled RNA and the quality of the hybridisation data are presented in Supplemental Figure S1. Using the Affymetrix two-cycle amplification method we are able to produce ≥15 µg cRNA using starting amounts as low as 0.1 ng; below this level the output drops significantly. The product size decreases as smaller amounts of RNA are used, resulting in 5’ truncation of the cRNA and the subsequent loss in detection of genes with probes directed towards the 5’ end of the gene. On the basis of these tests, we used between 10 ng to 100 ng of starting material in our experiments to minimise 5’ truncation of the cRNA transcripts.

Experimental set up
Our aim was to compare gene expression changes between normal and smn mutant animals and tissues. The strong genetics of Drosophila make it possible to use a “normal” background that is genetically very close to the mutant, this genetic system is thus highly appropriate for genomic analysis. In this study we used a mutant allele of smn that was recombined onto an isogenised third chromosome background [see Materials and methods]; the smn mutant animals or isolated tissues will be homozygous for this allele. The control “normal” background was the same isogenised chromosome in homozygous state, but without the smn mutation. The other chromosomes are free to drift genetically in both normal and smn mutant strains.

To obtain information on the time frame of molecular changes in the smn mutant background and thus when to isolate our samples, we have assessed the neuromuscular tissues in second and third instar larval stages. Motor defects in the smn mutant animals are first seen halfway between these stages and are statistically significant by third instar. At this life stage, we have previously reported that clustering of the neurotransmitter receptor is disrupted at the neuromuscular junction (NMJ) [7]. Disruption of neurotransmitter receptor clustering has also been reported in patient tissue [8] and in a recently described mouse model [9]. On our time course, in early second instar larvae the accumulation of clusters of the neurotransmitter receptor, Glutamate receptor IIIA (GluR IIA), is similar in mutant animals compared to controls (Figure 1). By late second stage the number and size of clusters in the mutant tissues changes compared to the controls. By the time that the larvae display motility problems (third instar) this difference is exacerbated, leaving very few clusters in the mutant situation. These results argue that the loss of motility in our animals is concomitant with or proceeded by a loss of neurotransmitter receptor clustering at the NMJ after an initially normal pattern. Thus molecular defects are visible from late second instar and increase into third instar stage, note however that even at mid-to-late third instar stage little tissue degeneration is observed (unpublished and see [7]). We used animals at the second and third instar stage for whole animal gene expression analysis and concentrated on individual tissues at the later stage only. The loss in neurotransmitter receptor clustering is most clearly seen at the later stage and since this defect has been shown in other model systems and patients, it would be most interesting to explore in our experimental analysis.

For tissue samples, we dissected muscle tissue and motor neuron cell bodies from mobility impaired third instar larvae. The ventral abdominal muscles were obtained by filleting larvae and removing gut, neurons and dorsal muscles, the ventral muscles were dissected from the remaining cuticle. The cell bodies of the motor neurons are found in the ventral ganglion as part of the brain structure in the larva; this tissue was dissected out. The whole larvae and tissue samples were processed to generate labelled cRNA.

We used the GC-RMA (Robust Multi-array Analysis) method to normalize the hybridisation results; this method uses the GC content of the probes to reduce variance in the mismatch (control) probe levels as spotted on the Affymetrix arrays [10].

Hybridisation results
We combined the results across the various samples to identify overlapping changes in gene expression. Any overlap patterns would allow trends to be uncovered. Common disruptions might point to an affected function in SMN deprived tissues. We used a 1.5 fold change in expression as cut-off in these comparisons and stringent statistics. We compared the expression changes for brain and muscle tissues to the whole animal data. If the role of SMN in SMA is linked to a general function that SMN performs in all cells then a transcriptional response to reduced activity might be seen in all cells of the animal. Conversely, changes specific to either muscle and/or brain might point to genes that influence the tissue specificity of SMA (see Gene Pathway Changes paragraph). The number of genes that change in these comparisons is shown in Table 1, and the genes listed in supplemental Figure S2, S3, S4, S5, S6, S7, S8, S9 and S10.

The number of genes in common between the tissue and whole animal samples is small; each tissue sample itself shows consistently the largest number of gene expression changes (“No change in larvae” row). This might reflect the fact that the lowered levels of smn activity specifically affect the neuromuscular tissues; gene expression changes specific to these tissues could fall below the cut-off levels in the whole animal samples. We have previously assessed the sensitivity of the muscle and neuronal tissues in a genetic
experiment. A transgene encoding Smn was expressed in a homozygous smn mutant background. As expected rescue was almost 100% by ubiquitous expression of the transgene, however, interestingly, significant rescue was also observed when the transgene was expressed solely in muscle and neurons. These results showed clearly that these specific tissues in the fly are more sensitive to the levels of smn compared to the rest of the animal [7].

Although it is difficult to concentrate on individual genes at this point, we will highlight some here. Across all samples, three genes encoding cytochrome P450 domains are up-regulated as well as two Glutathione S transferases. Interestingly two genes that encode G-protein-coupled-receptor-like proteins, amenable drug targets, with unknown function are uniformly up-regulated. Amongst the genes that are down regulated, different family members of Glutathione S transferase (CG6776) and cytochrome P450 (or electron transport, CG4511) encoding genes are found. Within the down-regulated genes in the muscle a gene that has predicted RNA cap binding function is found (CG8023).

The larval samples were taken at two time points and this enables us to investigate the changes in gene expression across time. Many genes that have been annotated but not functionally analysed are identified in this way. Within these, a trend is recognizable towards a down-regulation of metabolic and transporter activities. Some genes associated with immune response are found up-regulated. In both brain and muscle samples (and whole larvae) a gene annotated as N-methyl-D-aspartate receptor associated protein is up-regulated, only at the later stage. This might indicate a link with the reduced accumulation of Glutamate Receptors at the mutant NMJs in the mutant animals. A protein known to function in transcript transport and translation control, spire, is up-regulated at the earlier stage in muscle only.

When looking only at the tissues samples, it appears that there are more genes showing expression changes in muscle than in brain samples. The overlap between muscle and brain samples will uncover gene expression changes specific to the neuromuscular system. The lower rows in Table 1 show the number of genes changing and the genes are listed in supplemental Figures S2, S3, S4, S5, S6, S7, S8, S9 and S10. Within the down-regulated genes two syntaxin encoding genes are identified. Interestingly, three genes encoding small Heat Shock Proteins are down-regulated especially in the muscle sample.

To further understand whether SMN is required specifically in the neuromuscular tissues, we have assessed the expression of the smn gene in these tissues versus the rest of the animal using both our array data and Real-Time Polymerase Chain Reaction (RT-PCR) analysis. This latter method compared the concentration of the smn transcript in larval and adult tissues against non-changing control genes. This analysis clearly shows that expression of smn is higher in larval and adult neuromuscular tissues, with especially high expression in the nervous system (Figure 2).

The molecular analysis of the NMJs in the smn mutant clearly showed a deregulation of GluR protein accumulation (GluR IIA subunits). Using our data, we assessed the changes in expression of some of the GluR genes (Table 2). GluR IIA and IIB, for which protein is found at the NMJ, are mildly down regulated in smn mutant muscle. GluR III (also known as IIC) is up-regulated in smn mutant muscle and no change is seen for GluR IID. All have a p value ≤0.05 of change between controls and smn mutant muscle in a Welch t-test.

Figure 1. Confocal Scanning Fluorescent images of Drosophila neuromuscular junctions. A to C, early second instar larvae; D to F, late second instar larvae and G to I, third instar larvae (mid stage). A, D and G, normal (+/+), larvae, B, C, E, F, H and I, smn mutant larvae (smn/smnn). A, B, D, E, G and H stained for Glutamate receptor subunit; C, F and I stained for a pre-synaptic marker (syntaxin). Comparing the accumulation of receptor clusters in the normal tissue across time to the mutant tissues, it is clear that the mutant displays a reduced number of glutamate receptor clusters across time. doi:10.1371/journal.pone.0001404.g001
It has been suggested that the formation of functional receptors requires at least GluR III and one of either IIA or IIB (and possibly other sub units) [11]. The significant up-regulation we observe for GluR III might be a response of the animal to the reduction of receptor activity at the NMJ. The reduction in transcripts for the IIA subunit cannot explain the degree of loss of clustering we see at the neuromuscular junction, arguing the problem in the SMN depleted tissue is not primarily based on transcript reduction.

Validation of array results
To assess the validity of our hybridisation results we examined the expression of a number of genes, randomly picked from our list, of differentially expressed genes using Real Time Polymerase Chain Reaction (RT-PCR) amplification. Strong correlation between PCR expression data and micro array values was found (Figure 3). All changes determined by RT-PCR were statistically significant in a Student’s t-test ($n = 3$ and 4 for whole larvae and muscle respectively) and consistent with the direction of change reported by the micro-array analysis.

Gene pathway changes
To explore functional changes within neuromuscular tissues we used Gene Ontology (GO) analysis to identify molecular pathways that were up- or down-regulated in smn mutant tissues versus control. Figure 4A shows a selection of categories in muscle and brain tissues where respectively ≥ 20% and ≥ 10% of genes per category are changed with a P value of ≤ 0.05 (Supplemental Figures S11 and S12 show the full list of GO terms in muscle and brain tissues, up and down regulated).

We find GO terms associated with NMJ physiology and locomotion down regulated in the brain tissue while terms involving general and tRNA metabolism are up regulated. In the muscle samples, terms associated with cellular transport and degradation are down-regulated. In addition neurotransmitter associated terms are down regulated.

Interestingly within the up-regulated genes in the muscle, very clear clustering of terms associated with energy metabolism is observed. Out of the highly significant terms (more than 50% of genes in a selected class are changing) more than half are associated with energy generation and mitochondrial activities. The other very clear grouping that is found up-regulated in the muscle is associated with RNA metabolism. RNA polymerase activity, RNA helicase as well as tRNA synthesis are found amongst the highly significant changes. The established function of SMN in RNA metabolism makes this an interesting observation. This possibly relates to the following. Comparing the muscle and brain samples, the gene expression changes in the muscle are often more significant and a considerable larger number of genes is found changed in muscle versus brain. These observations indicate that the effect of the reduction of SMN activity leads to a more pronounced response in muscle than in brain.

To study the temporal response to low SMN activity in the whole organism, we compared the GO terms in the 2nd and 3rd instar samples (using 20% cut off per category). The results are shown in Figure 4B (the full lists are shown in Supplemental Figures S13 and 14). Most changes in GO terms replicate across these samples, this strongly indicates that these reflect real responses to a reduction in SMN. In the down-regulated genes many terms fall into the category of metabolic, especially carbohydrate, enzyme activities. This indicates that the animals are possibly slowing their metabolic rate. Consistent with this we have observed that the mutant animals become emaciated.

In the up-regulated genes, interestingly, moving from the earlier time point to the later, terms associated with lytic activities are identified. This might indicate that the muscle tissues are very sensitive to the continued reduction in SMN activity and become degenerative (although no obvious signs are present on the tissue level).

Genetic interactions
Our experiments show that expression of certain genes changes dramatically in smn depleted tissues. The function of SMN has been shown to involve the assembly of RNA-protein complexes [5,12]. Rather than direct influences of SMN on gene transcription, the changes in gene expression we observe are therefore likely to be indirect due to the reduction of SMN activity. Such changes could be associated with an attempt within the tissues to maintain normal activity in the presence of depleted SMN function. Genes that are found up-regulated could perform a rescue function in the tissue. Reversely the down regulation of certain genes could be associated with the tissue reducing the activity of pathways that are disadvantageous at low levels of SMN. Agonists and antagonists to the function of these genes could aid the tissues in their struggle against phenotypes caused by low levels of SMN.

To further understand our findings and progress them into a functional realm we performed genetic experiments. We set out to prove if we could identify direct genetic interactions of loci corresponding to isolated genes, with smn. We combined an smn

**Table 1.** Table showing the number of gene expression changes at cut-off of ≥1.5 fold, in common between tissues indicated and larvae of different stages.

| Table 1a Larvae/brain comparisons |
|----------------------------------|
| 2nd instar larvae | 3rd instar larvae | Brain | No. genes |
| No change | No change | Up | 436 |
| Up | No change | Up | 27 |
| No change | Up | Up | 55 |
| Up | No change | Up | 22 |
| No change | No change | Down | 334 |
| Down | No change | Down | 22 |
| No change | Down | Down | 13 |
| Down | Down | Down | 17 |

| Table 1b Larvae/Muscle comparisons |
|----------------------------------|
| 2nd instar larvae | 3rd instar larvae | Muscle | No. genes |
| No change | No change | Up | 1184 |
| Up | No change | Up | 30 |
| No change | Up | Up | 98 |
| Up | No change | Up | 28 |
| No change | No change | Down | 1363 |
| Down | No change | Down | 63 |
| No change | Down | Down | 45 |
| Down | Down | Down | 30 |

| Table 1c Brain/muscle comparisons |
|----------------------------------|
| Brain | Muscle | No. genes |
| Up | Up | 217 |
| Down | Down | 185 |

Table showing the number of gene expression changes at cut-off of ≥1.5 fold, in common between tissues indicated and larvae of different stages. Both larval stages, and gene expression changes at ≥1.5 fold that are not seen in larvae are shown, as well as changes in common only between Brain and Muscle samples. All changes have a p-value of ≤ 0.05 in a two-tailed two-sample Welch t-test.

* doi:10.1371/journal.pone.0001404.0001

It has been suggested that the formation of functional receptors requires at least GluR III and one of either IIA or IIB (and possibly other sub units) [11]. The significant up-regulation we observe for GluR III might be a response of the animal to the reduction of receptor activity at the NMJ. The reduction in transcripts for the IIA subunit cannot explain the degree of loss of clustering we see at the neuromuscular junction, arguing the problem in the SMN depleted tissue is not primarily based on transcript reduction.

Genetic interactions
Our experiments show that expression of certain genes changes dramatically in smn depleted tissues. The function of SMN has been shown to involve the assembly of RNA-protein complexes [5,12]. Rather than direct influences of SMN on gene transcription, the changes in gene expression we observe are therefore likely to be indirect due to the reduction of SMN activity. Such changes could be associated with an attempt within the tissues to maintain normal activity in the presence of depleted SMN function. Genes that are found up-regulated could perform a rescue function in the tissue. Reversely the down regulation of certain genes could be associated with the tissue reducing the activity of pathways that are disadvantageous at low levels of SMN. Agonists and antagonists to the function of these genes could aid the tissues in their struggle against phenotypes caused by low levels of SMN.

To further understand our findings and progress them into a functional realm we performed genetic experiments. We set out to prove if we could identify direct genetic interactions of loci corresponding to isolated genes, with smn. We combined an smn
heterozygous mutant background with either mutant backgrounds (where available) and/or with over-expression constructs of random genes out of our lists. The selection of loci from our lists was random except for the fact that we were limited by the availability of genetic aberrations for selected genes. Table 3 shows the genes selected and the results of these genetic tests.

The test we used relies on subtle changes in the survival of the offspring. This test is relevant to the patient situation but it is only partially probing any functional interaction. On the other hand we examined a significant number of individuals in our test, generating a statistically more relevant outcome. We could also not assess if the aberrations we used here actually disrupt (or enhance) the activity of the indicated gene (note that numbered genes are only annotated as a gene and there are no functional data).

Despite these calculated setbacks, we clearly identified some genetic interactions with SMN in these tests and these will be discussed below.

### Table 3: Gene Selection and Results

| Sample   | Control | Smn<sup>+</sup> |
|----------|---------|-----------------|
| 2<sup>nd</sup> instar | 40      | 37              |
| 3<sup>rd</sup> instar | 17      | 15              |
| Muscle   | 187     | 87              |
| Brain    | 1129    | 743             |

### Figure 2. Smn gene expression analysis using two different methods.

A) Results of micro-array hybridisations. “Sample” column lists the different RNA samples used for cRNA preparation. The control and Smn mutant relative concentrations are shown. Expression is low in the RNA samples derived from whole animals but is significantly higher in neuromuscular tissues, especially in brain. The expression is reduced by 1.9 and 1.5 fold in the mutant animals in muscle and brain respectively. Note that these tissues are mutant for the somatic gene (a point mutation so transcripts will be produced) while still containing detectable maternal RNA (data not shown). B) Real-Time-PCR analysis of Smn expression across different tissues. The Bar figure shows the relative abundance of Smn transcript in tissues versus either whole animals (thus containing the isolated tissues; all third instar larval stage derived) or versus isolated gut tissue (all adult derived), all from Smn<sup>+</sup>/+. In both Central Nervous System (CNS) and muscle the expression of Smn is higher. C) The significance of this finding increases in adults. doi:10.1371/journal.pone.0001404.g002

### Table C: Statistical Comparisons

| Comparisons                  | T Value | P    | Significance |
|------------------------------|---------|------|--------------|
| Larval CNS vs Whole Larvae   | 7.10    | 0.001** |
| Larval Muscle vs Whole Larvae| 3.09    | 0.027*  |
| Adult CNS vs Adult Gut       | 9.13    | 0.001***|
| Adult Muscle vs Adult Gut    | 6.52    | <0.001** |
discuss the technical difficulties in microarray experiments of working with small amounts of tissue material, inherent to working with Drosophila, are surmountable. This has led to statistically relevant and high quality data, which we independently verified using direct transcript level measurements.

Here we present a study of genome-wide transcription changes in a neurotransmitter receptor at the SMN-depleted fly neuromuscular interaction of small HSP genes with neuromuscular disorders. [13,14]. These findings hint at a close and perhaps general Tooth disease, the most common inherited neuromuscular disease have been pinpointed as leading to a form of Charcot-Marie- Tooth disease, the most common inherited neuromuscular disease associated with the mitochondrion are strongly affected. In addition, our results also show for the first time, by using Gene Ontology analysis, another set of terms are mostly up-regulated and include many mitochondrial localized processes. It appears that the depletion of SMN function leads to metabolic changes in the animal.

Small Hsp genes provide activity to rescue cells under duress and three such genes are isolated in muscle and brain tissues as associated with basic metabolism. Some are transcription oriented (human disease) genes in simple model organisms. In addition, the technology with genetics will be useful in the functional analysis of general level, we feel that this type of analysis, combining genomic characterisation of hitherto unknown functional relations between genes. We have used fly genetics to find new genes interacting with SMN, by selecting loci from our array results and combining these in a simple assay with the smn mutant locus in the fly. The number of genes (and available mutations) does not allow for an extensive study, however even in our limited analysis we have found evidence for genetic interaction with some genes.

Because of the large number of genes representing metabolic functions, our genetic analysis contains several of these. Interestingly however all loci that appear positive in our test (Be [Black cells], Lag1, Aldh [Aldehyde dehydrogenase], ste [shuttle craft], und [uninitiated] and bao [brother of odd with entrails limited] are in some way functionally associated with basic metabolism. Some transcription oriented some are associated with basic enzymatic functions. We would conclude that although our test sample was small that metabolism is an important factor in determining the overall survival of the smn mutant animals and therefore possibly of SMA patients. On a more general level, we feel that this type of analysis, combining genomic technology with genetics will be useful in the functional analysis of (human disease) genes in simple model organisms. In addition, the continuous and rapid increase in molecularly characterised mutations in random genes in the fly, will make the resources reported here useful for further SMA functional studies.

**Materials and Methods**

**Fly strain used**

Our lab had obtained a mutant in the smn gene by analyzing candidate recessive-lethal mutants in the region where the gene is located based on genome annotation (73A7-9) [7]. Sequence analysis showed that one of the many lethal mutations in this region, the mutant l(3) 73Ao, contained a point mutation in the coding region of smn, resulting in a mis-sense mutation. Our lab recombined this smn27Ao mutant background with an isogenized stock to remove any unwanted lethal mutations in the genetic background (on the same chromosome). The resulting smn27Ao mutant was homozygous lethal at third larval stages.

The (normal) control used is the isogenic background on which the smn mutant background was recombined.

Both lines were maintained using standard conditions. For collection of material, flies were housed on apple juice plates with yeast in 25°C incubator with 10hrs light-14 hrs dark cycle. Times larvae were isolated using genetic markers or Green Fluorescent Protein (expressed on the non-mutant allele, homozygous mutants will not light up green).

**Table 2. Fold changes of GluR genes in smn mutant muscle compared to wild type muscle (p value ≤0.05 of a difference between the 2 conditions).**

| Glutamate receptor | Affymetrix probe ID | Fold change |
|-------------------|---------------------|-------------|
| IA                | 143498_at          | −2.35       |
| II B              | 143926_at          | −1.82       |
| III (IIC)         | 152969_at          | 4.3         |
| III D             | 150272_at          | no change   |

*Fold changes of GluR genes in smn mutant muscle compared to wild type muscle (p value ≤0.05 of a difference between the 2 conditions). The GluR IID gene is also known as KaiRIA. doi:10.1371/journal.pone.0001404.t002*
Immunolabelling

For detection of specific proteins at the neuromuscular junction, we used antibodies against Smn protein (described in Thomas et al., under consideration) and syntaxin (see acknowledgements) on dissected tissues (as above) fixed using 4% paraformaldehyde. Incubations of antibodies (including secondary detection antibodies obtained from Molecular Probes/Invitrogen) were done in 1xPBS+0.1% Tween 20 and 0.3% saponin.

Sample collection

In total, we collected four samples for RNA isolation. The first sample is 2nd instar larvae, second sample is 3rd instar larvae. We selected female larvae (on basis of externally visible markers for 3rd instar, for 2nd instar we took 10 larvae total) in order to avoid any sex-related gene expression changes between samples. The larvae were rinsed twice in 1xPBS (to wash off any bacteria or yeast) before RNA preparation (see below). The third and fourth samples...
are the 3rd instar female larval brains and abdominal ventral muscle. Both tissues were dissected from the larvae in 1xPBS, and stored in RNAlater RNA Stabilization Reagent at 280°C. Three biological replicates of larvae were prepared and four biological replicates of brain and muscle.

RNA preparation
Total RNA was extracted from 2nd and 3rd instar larvae using the Qiagen RNeasy Mini Kit. The animals were homogenized in 350 μL RLT buffer (+β-Mercapto-Ethanol: ME) with a hand held homogenizer (5 mm probe blades) and the manufacturers protocol was followed for further isolation.

Total RNA was extracted from brain and muscle tissues using the Qiagen RNeasy Micro Kit, as above.

RNA concentration and integrity were assessed by absorbance at 260 and 280 nm and by an Agilent Bioanalyzer RNA 6000 Nano Assay (data not shown).

Sample labelling and hybridisation to Affymetrix array
Samples were prepared for Affymetrix analysis from whole 2nd and 3rd instar larva using 1 μg starting RNA. The Affymetrix One-Cycle Target Labelling and Control kit (P/N 900494) was used according to protocol 701027 Rev. 4 in the Affymetrix Eukaryotic Sample and Array Processing Manual. For Drosophila larval brain and muscle 100 ng and 40 ng starting RNA were used respectively. To successfully generate sufficient labelled cRNA for microarray analysis two rounds of amplification were necessary. For this the Affymetrix Two-Cycle Target Labelling and Control kit was used (P/N 900494) according to the manufacturer’s instructions described in the Affymetrix Eukaryotic Sample and Array Processing Manual version 701027 Rev.5. For the first cycle of in vitro transcription the Ambion MEGAscript T7 kit (P/N 1334) was used as detailed in the Affymetrix manual. Labelled cRNA was hybridised to Drosophila 1 chips and arrays were washed and then scanned using the Affymetrix GeneChip Scanner3000.

Analysis of differential gene expression
Microarray data were GCRMA normalised independently for each tissue using GeneSpring GX (Agilent). Differentially expressed genes were identified using a Welch t test with a p value cut off of ≤0.05 and a fold change difference between wild type and mutant smn of ≥1.5.

Real-Time RT-PCR (SYBR green)
Total RNA from WT and smn mutant whole 3rd instar larvae and muscle was used as a template for RT-PCR to independently assess the validity of Affymetrix GeneChip data. 10 ng 3rd instar total larval RNA and 1 ng larval muscle RNA per sample was used to synthesise first-strand cDNA, using random hexamers and SuperScript III reverse transcriptase (Invitrogen). The cDNA was used for quantitative real-time polymerase chain reaction (PCR) amplification with Sybr Green chemistry (Applied Biosystems). Primer Express software (Applied Biosystems) was used to design

Figure 4. A) A selection of Gene Ontology terms associated with up (red)- or down (green) -regulated genes in muscle and brain tissues, comparing normal with smn mutant. B) A selection of Gene Ontology terms associated with up- or down-regulated genes in 2nd and 3rd instar larvae, comparing normal with smn mutant, same colour-coding. For both A) and B) full lists of these terms are shown in Supplemental Figure S3.
Table 3. Results of genetic experiments where smn mutant allele and alleles named in 2nd column were combined in trans-heterozygous combination and welfare and survival were tested by counting the number of individuals of each genotype.

| Gene/Down-regulated | Putative Disruption used | Result  |
|---------------------|--------------------------|---------|
| l(2)ik9913          | BL12194                  | negative|
| CG5630              | BL13026                  | negative|
| Zw                  | BL4153                   | negative|
| CG1941              | BL10535                  | negative|
| CG17838             | BL10721                  | negative|
| Pgd                 | BL11970                  | negative|
| l(1)G0320           | BL11970                  | negative|
| CG1041              | BL17954                  | negative|
| 8c                  | BL12276                  | negative|
| Lag1                | BL12276                  | weak    |
| CG3823              | BL16489                  | negative|
| CG7115              | BL14190                  | negative|
| Aldh-III            | BL11342                  | very weak|
| CG12730             | BL13004                  | negative|
| CG60028             | BL14000                  | negative|

Gene/Up-regulated

| Gene/Up-regulated | Putative Disruption used | Result  |
|-------------------|--------------------------|---------|
| GstE7             | BL17923                  | negative|
| mthl3             | BL5574                   | negative|
| CG12505           | BL12770                  | negative|
| CPTI              | BL13731                  | negative|
| CG6214             | BL14544                 | negative|
| ab                | BL10520                  | unclear |
| CG1882            | BL13732                  | negative|
| HmgS              | BL11469                  | negative|
| stc               | BL11408                  | very weak|
| kraken            | BL13284                  | negative|
| CalpA             | BL13868                  | negative|
| Itbp9            | BL12836                  | negative|
| Hlc               | BL4731                   | unclear |
| pelo             | BL11757                  | negative|
| CG7461           | BL18095                  | negative|
| CG11107           | BL12911                  | unclear |
| und               | BL6297                   | very weak|
| bowl             | BL7094                   | weak    |
| h                | BL5529                   | negative|
| LX6               | BL14934                  | negative|

Results of genetic experiments where smn mutant allele and alleles named in 2nd column were combined in trans-heterozygous combination and welfare and survival were tested by counting the number of individuals of each genotype. A positive score would be an outcome of more than 10% less individuals of the trans-heterozygous background compared to the normal alleles. Loci listed as negative did not show any genetic interaction in this test. The genes mentioned in column one are abbreviated and/or annotation or full names can be found on http://flybase.bio.indiana.edu/. On average more than 250 offspring were counted.

doi:10.1371/journal.pone.0001404.t003

The thermal cycle conditions were 50°C for 2 min, 95°C for 10 min, 40 cycles of 15 s at 95°C followed by 1 min at 60°C. Immediately after the amplification, melt curve protocols were performed to ensure that primer-dimers and other non-specific products had been minimized or eliminated. A standard curve of cycle thresholds using serial dilutions of cDNA samples was established and used to calculate the relative abundance of the target gene in WT and mutant smn samples. Values were normalized to gamma-Tubulin (at map position 23C), we used this gene as its expression was not changing in our Affymetrix data. Minus RT samples tested simultaneously with experimental samples by quantitative RT-PCR with Sybr Green consistently yielded no amplification below 30 cycles using the above protocol.

Real-time RT-PCR (Probe)

Real-time quantitative PCR was performed by using TaqMan TAMRA probe chemistry on the ABI Prism 7000 Sequence Detector System (Applied Biosystems). Primers and probes were designed using Primer Express V2.0 software. Thermal Cycling parameters were 95°C for 10 min, followed by 40 cycles of 95°C for 1 minute, 59°C for 1 minute, and 72°C for 45 s. Aliquots of 50 µl consisting of primers, probes, cDNA and TaqMAN RT PCR master mix were run in triplicate on the Applied Biosystems 7000 sequence detection system. Primers were used at 900 nM concentration and probes at 20 nM concentration for both target and control. A serial dilution for each target gene was run on each plate in triplicate. The dilution series consisted of cDNA at 2 ng 1 ng, 0.5 ng 0.2 ng, 0.1 ng, 0.05 ng, and 0.02 ng concentrations. Data was analysed using the comparative relative quantification method and samples were normalised to both Actin42A and GAPDH. Three plates were run for this experiment.

Table 4. Probe and Primer Sequences for Real-Time PCR

| mRNA     | Sequence (5'-3') | Accession number |
|----------|------------------|------------------|
| Tubulin 23C | Forward AGTCCGGCAATCAATTGG | NM_057456      |
|          | Reverse GCTCCAGCCACAACTTCC |               |
| Mthl3    | Forward GAAAGTAGAAGAGAGACACAAAC | NM_145335 |
|          | Reverse GGACAGCCCATGATGAAAGA |               |
| CG6776   | Forward CGGGCAGGCAAGAGTTCTT | NM_139977 |
|          | Reverse TGGCCCTGCAAAGAGTGGT |               |
| CG4511   | Forward AGAACAGGGAGTGCTCAGAA | NM_141769 |
|          | Reverse AAACATGTTGGCCGACCTT |               |
| Tsp42Ed  | Forward GCGGGGTGTTTGTGAATAATG | NM_078906 |
|          | Reverse TATGTGGAGAGGAGGTAAGAA |               |
| CG6836   | Forward AGCCGGGCTCATCTTACCA | NM_136929 |
|          | Reverse CTGTCGTCGTTTCCATAGTT |               |
| Cyp4ac3  | Forward GCCATGTGAGGACCTCCTTTT | NM_135074 |
|          | Reverse GGTATGTGATCCCCGCAACAT |               |
| CG4778   | Forward CCTCACCACATTGACCTGATGA | NM_135495 |
|          | Reverse GGCTCTGCTGGCCGAAGAT |               |
| Gip      | Forward CGATAACCGTTAGAGGCGAACAT | NM078551 |
|          | Reverse ATTCCAGGGCTTGAGGAT |               |

doi:10.1371/journal.pone.0001404.t004

primers from the RefSeq sequences. The target gene names, RefSeq numbers and primer sequences are shown in Table 4. Triplicate cDNA template samples were amplified and analyzed in the Prism 7000 sequence detection system (Applied Biosystems).
SUPPORTING INFORMATION

Figure S1  cRNA yields and quality from decreasing amounts of starting RNA. A) The yield of cRNA falls steeply when the amount of starting material goes below 1 ng. B) The size distribution is smaller when the 2 cycle labelling kit is used for 100 ng RNA compared with cRNA transcripts generated using the 1 cycle kit for 5 ug starting RNA. The smaller the amount of starting RNA the smaller the transcripts that are generated. C) Scatter plots show some genes decrease in signal when smaller amounts starting amounts of RNA are used. This was shown to be due to 5' truncation of cRNA transcripts, preventing complete hybridisation to the rarer 5' probe sets (data not shown). However the loss of gene expression signal resulting from reduced starting material may not always translate into changed gene expression changes. Found at: doi:10.1371/journal.pone.0001404.s001 (0.70 MB DOC)

Figure S2  Genes identified in brain tissue, not in 2nd and 3rd instar larvae, corresponding to 1st and 5th rows in Table 1a. Found at: doi:10.1371/journal.pone.0001404.s002 (0.09 MB XLS)

Figure S3  Genes identified in 2nd instar larva and brain tissue, not in 3rd instar larva, corresponding to 2nd and 6th rows in Table 1a. Found at: doi:10.1371/journal.pone.0001404.s003 (0.02 MB XLS)

Figure S4  Genes identified in 3rd instar larva and brain, not in 2nd instar larva, corresponding to 3rd and 7th rows Table 1a. Found at: doi:10.1371/journal.pone.0001404.s004 (0.02 MB XLS)

Figure S5  Genes identified in brain, 2nd and 3rd instar larva, corresponding to 4th and 8th rows in Table 1a. Found at: doi:10.1371/journal.pone.0001404.s005 (0.02 MB XLS)

Figure S6  Genes identified in muscle tissue, not in 2nd and 3rd instar larva, corresponding to 1st and 5th rows in Table 1b. Found at: doi:10.1371/journal.pone.0001404.s006 (0.26 MB XLS)

Figure S7  Genes identified in 2nd instar larva and muscle tissue, not in 3rd instar larva, corresponding to 2nd and 6th rows in Table 1b. Found at: doi:10.1371/journal.pone.0001404.s007 (0.02 MB XLS)

Figure S8  Genes identified in 3rd instar larva and muscle, not in 2nd instar larva, corresponding to 3rd and 7th rows in Table 1b. Found at: doi:10.1371/journal.pone.0001404.s008 (0.03 MB XLS)

Figure S9  Genes identified in muscle, 2nd and 3rd instar larva, corresponding to 4th and 8th rows in Table 1b. Found at: doi:10.1371/journal.pone.0001404.s009 (0.02 MB XLS)

Figure S10  Genes identified as in common between brain and muscle samples, corresponding to last two rows in Table 1c. Found at: doi:10.1371/journal.pone.0001404.s010 (0.06 MB XLS)

Figure S11  Gene Ontology (GO) collective terms for genes that are differentially regulated in SMN mutant muscle with a 1.5 fold cut-off. Terms are selected only if 20% or more of genes in a GO term are changed. Found at: doi:10.1371/journal.pone.0001404.s011 (0.08 MB XLS)

Figure S12  Gene Ontology (GO) collective terms for genes that are differentially regulated in mutant SMN brain with a 1.5 fold cut-off, GO terms are selected only if 10% or more of genes in a GO term are changed. Found at: doi:10.1371/journal.pone.0001404.s012 (0.03 MB PPT)

Figure S13  Gene Ontology (GO) collective terms for genes that are differentially regulated in SMN mutant 2nd instar larva with a 1.5 fold cut-off. Terms are selected only if 20% or more of genes in a GO term are changed. Found at: doi:10.1371/journal.pone.0001404.s013 (0.02 MB XLS)

Figure S14  Gene Ontology (GO) collective terms for genes that are differentially regulated in SMN mutant 3rd instar larva with a 1.5 fold cut-off. Terms are selected only if 20% or more of genes in a GO term are changed. Found at: doi:10.1371/journal.pone.0001404.s014 (0.02 MB XLS)

ACKNOWLEDGMENTS

The (monoclonal against syntaxin) developed by dr. Seymour Benzer was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. We would like to thank Prof. Kay E. Davies for allowing us to use the OXION facilities.

Author Contributions

Conceived and designed the experiments: Mv SG SL. Performed the experiments: AS SG SL HB. Analyzed the data: AS SG SL HB. Contributed reagents/materials/analysis tools: Mv SL. Wrote the paper: Mv.

REFERENCES

1. Lefebvre S, Burgen L, Reboullet S, Clermont O, Burlet P, et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80: 155–165.
2. Lefebvre S, Burlet P, Liu Q, Bertrand S, Clermont O, et al. (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nature Genetics 16: 265–269.
3. Schrank B, Gotz R, Gunningen JM, Ure JM, Toyka KV, et al. (1997) Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy 1 patients. Laboratory Investigation. pp 1–8.
4. Yong J, Wan L, Dreyfuss G (2004) Why do cells need an assembly machine for RNA-protein complexes? Trends in cell biology 14: 226–232.
5. Gubitz AK, Feng W, Dreyfuss G (2004) The SMN complex. Experimental cell research 296: 51–56.
6. Chan YB, Miguel Aliaga I, Franks C, Thomas N, Trulzsch B, et al. (2003) Neuro muscular defects in a Drosophila survival motor neuron gene mutant. Human molecular genetics 12: 1367–1376.
7. Arnold AS, Gaye M, Guertier-Sugist S, Courdier-Fruh I, Coupin G, Pouinat P, Gies JP (2004) Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy 1 patients. Laboratory Investigation, pp 1–8.
8. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, et al. (2005) SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Human molecular genetics 14: 845–857.
10. Shedden K, Chen W, Kuick R, Ghosh D, Macdonald J, et al. (2005) Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC bioinformatics 6: 26.

11. Qin G, Schwarz T, Kittel RJ, Schmid A, Kase TM, et al. (2005) Four different subunits are essential for expressing the synaptic glutamate receptor at neuromuscular junctions of Drosophila. Journal of neuroscience the official journal of the Society for Neuroscience ISSN (ELECTRONIC VERSION): 1529 2401 25: 3209–3218.

12. Monani UR (2005) Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron ISSN (PRINT VERSION): 0896 6273 48: 885–895.

13. Evgrafov OV, Meriyanova I, Irobi J, Van Den Bosch L, Dierick I, et al. (2004) Mutant small heat-shock protein 27 causes hereditary motor and distal hereditary motor neuropathy. Nature genetics 36: 602–606.

14. Irobi J, Van Impe K, Seeman P, Jordanova A, Dierick I, et al. (2004) Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nature genetics 36: 597–601.

15. Zhang HL, Pan F, Hong D, Shenoy SM, Singer RH, et al. (2003) Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. Journal of neuroscience the official journal of the Society for Neuroscience 23: 6627–6637.

16. von Lewinski F, Keller BU (2005) Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends in neurosciences 28: 494–500.

17. Verstreken P, Bellen HJ (2002) Meaningless minis? Mechanisms of neurotransmitter-receptor clustering. Trends in neurosciences 25: 393–395.

18. Featherstone DE, Rushton EM, Hilderbrand-Chae M, Phillips AM, Jackson FR, et al. (2000) Presynaptic glutamic acid decarboxylase is required for induction of the postsynaptic receptor field at a glutamatergic synapse. Neuron 27: 71–84.